Nanotherapeutics is a transformative field in modern medicine, utilizing nanotechnology to tackle some of the most challenging issues in drug delivery, gene therapy, and regenerative medicine.
As of October 28, 2024, the USPTO has published over 147,164 patent filings for FY 2024. Samsung, Huawei and Canon emerge as the top patent filers in the U.S.
The USPTO issued around 326,921 patents in FY 2024. Samsung, LG, TSMC emerge as top patent owners in the U.S. for 2024.
Researchers from the Korea Institute of Science and Technology (KIST) are looking to patent a system related to controlling avatars in real time within a virtual reality (VR) environment using a person’s biofeedback.
Tech giant Apple’s infringement of patented internet security technology could cost it over a billion dollars at the end of a decade-long legal battle, likened by its judge to the interminable Jarndyce v. Jarndyce case in the Charles Dickens novel Bleak House.
Irish technology licensing firm Neodrón announced in early January that it has settled with ten of the largest consumer electronics companies in the world.
Blackberry reportedly sold 90 of its patents to Huawei Technologies as part of the company’s broader strategy to streamline its operations by selling thousands of
Ping An Insurance Group and Philips were the world’s most prolific digital health patent applicants in the last three years, according to the China Digital Technology Development Working Committee (CDTC).
The UK’s Competition and Markets Authority (CMA) announced that it is launching an investigation into Nvidia’s planned USD40 billion acquisition of the UK-based Arm Limited from Softbank Group.
Korean tech giants, Samsung and LG lead with the most granted patents from January 9–15.
Services
Links
Sign up to receive first access to our reports, the latest patent news, and other updates —
all delivered to your inbox.
Sign up for our weekly newsletter featuring the latest patents and innovations.
Get early access to our patent landscape and insight reports.
Disclaimer:
1. Parola Analytics and Avontis are distinct entities and operate independently. Any references to Avontis or its services do not constitute a legal partnership.
2. Parola Analytics does not provide legal services. Our services are limited to research and technical analysis. Any information provided by Parola Analytics should not be construed as legal advice.